995 1030
Author contributions:
Giuseppe Magistro had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design:
Magistro, Gratzke.
Acquisition of data:
Magistro, Gratzke.
Analysis and interpretation of data:
Magistro, Chapple, Elhilali, Gilling,
Roehrborn, McVary, Stief, Woo, Gratzke.
Drafting of the manuscript:
Magistro, Chapple, Elhilali, Gilling, Roehrborn,
McVary, Stief, Woo, Gratzke.
Critical revision of the manuscript for important intellectual content:
Magistro, Chapple, Elhilali, Gilling, Roehrborn, McVary, Stief, Woo,
Gratzke.
Statistical analysis:
None.
Obtaining funding:
None.
Administrative, technical, or material support:
None.
Supervision:
Magistro, Chapple, Gratzke.
Other:
None.
Financial disclosures:
Giuseppe Magistro certifies that all conflicts of
interest, including specific financial interests and relationships and
affiliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/affiliation, grants or funding, consul-
tancies, honoraria, stock ownership or options, expert testimony,
royalties, or patents filed, received, or pending), are the following:
Chapple reports personal fees and nonfinancial support from Allergan,
grants, personal fees, and nonfinancial support from Astellas, personal
fees and nonfinancial support from Boston, personal fees and
nonfinancial support from Medtronic, personal fees from Pfizer,
personal fees and nonfinancial support from Recordati, outside the
submitted work. Gilling reports activity as study investigator and
meeting participant for PROCEPT BioRobotics Inc. McVary is a
consultant/investigator for Allergan, Lilly/ICOS, NxThera, NIDDK,
Astellas, Boston Scientific, and Sophiris. Woo reports personal fees
from Boston Scientific, other from NxThera, other from Neotract,
other from GSK, outside the submitted work. Gratzke reports grants/
honoraria/ consultation fees from Astellas, Bayer, GSK, MSD,
Recordati, Amgen, Ipsen, Janssen, Lilly Pharma, Recordati, Pfizer,
Rottapharm, and STEBA.
Funding/Support and role of the sponsor:
None.
References
[1]
Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemi- ology, economics and evaluation. Can J Urol 2015;22(Suppl 1): 1–6.[2]
Parsons JK, Wilt TJ, Wang PY, et al. Progression of lower urinary tract symptoms in older men: a community based study. J Urol 2010;183:1915–20.[3]
Centers for Disease Control and Prevention. Public health and aging: trends in aging–United States and worldwide. JAMA 2003;289:1371–3.[4] Gravas S, Bach T, Bachmann A, et al. EAU Guidelines on the Man-
agement of Non-Neurogenic Male Lower Urinary Tract Symptoms
(LUTS), incl. Benign Prostatic Obstruction (BPO). 2015.
http:// uroweb.org/wp-content/uploads/EAU-Guidelines-Management- of-non-neurogenic-male-LUTS-2016.pdf.
[5] McVary KT RC, Avins AL. American Urological Association Guide-
line: Management of Benign Prostatic Hyperplasia (BPH); American
Urological Association Education and Research, Inc. 2010.
http:// www.auanet.org/guidelines.
[6]
Bach T, Muschter R, Sroka R, et al. Laser treatment of benign prostatic obstruction: basics and physical differences. Eur Urol 2012;61:317–25.
[7]
Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): the endourologic alternative to open prostatectomy. Eur Urol 2006;49:87–91.
[8]
Kuntz RM. Current role of lasers in the treatment of benign prostatic hyperplasia (BPH). Eur Urol 2006;49:961–9.[9]
Naspro R, Bachmann A, Gilling P, et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol 2009;55: 1345–57.
[10]
Kluivers KB, Riphagen I, Vierhout ME, Brolmann HA, de Vet HC. Systematic review on recovery specific quality-of-life instruments. Surgery 2008;143:206–15.[11]
Myles PS, Hunt JO, Nightingale CE, et al. Development and psycho- metric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg 1999;88:83–90.[12]
Saemi AM, Folsom JB, Plante MK. Injection therapy for prostatic disease: A renaissance concept. Indian J Urol 2008;24:329–35.[13]
Andersson KE. Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol 2013;47:83–90.
[14]
Magistro G, Stief CG, Gratzke C. New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol 2015;12:461–71.
[15]
Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor over- activity/neurogenic overactive bladder: a systematic literature re- view. Eur Urol 2008;53:275–87.
[16]
Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol 1988;139:919–22.[17]
Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004;64:871–5, discussion 5.
[18]
Chartier-Kastler E, Mehnert U, Denys P, Giuliano F. Botulinum neurotoxin A for male lower urinary tract symptoms. Curr Opin Urol 2011;21:13–21.[19]
Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011;60:784–95.
[20]
Mangera A, Apostolidis A, Andersson KE, et al. An updated system- atic review and statistical comparison of standardised mean out- comes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014;65:981–90.
[21]
Oeconomou A, Madersbacher H. Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol 2010;20:28–36.
[22]
Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlarge- ment? A review of the literature. European urology 2008;54(4): 765–75.[23]
Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 2013;63:496–503.
[24]
Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003;62:259–64, discussion 64-5.[25]
McVary KT, Roehrborn CG, Chartier-Kastler E, et al. A multicenter, randomized, double-blind, placebo controlled study of onabotuli- numtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2014;192:150–6.[26]
Shim SR, Cho YJ, Shin IS, Kim JH. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic re- view and meta-analysis. Int Urol Nephrol 2016;48:19–30.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 8 6 – 9 9 7
995